Trial Profile
A retrospective study comparing the efficacy of everolimus, temsirolimus and sorafenib as a second line therapy in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary) ; Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 09 Dec 2015 New trial record